How Metabolic Disorders Drive Cardiomyopathies and How GLP-1/SGLT2 Drugs Can Help | Research

The takeaway

Metabolic disorders modulate cardiomyopathy genotype-phenotype expression through converging molecular mechanisms, with SGLT2i and GLP-1 RA representing therapeutic frontiers for pleiotropic cardiac remodeling.

Metabolism shapes genetics
Metabolic disorders modulate how cardiomyopathy genes express disease — treating metabolism with GLP-1/SGLT2 drugs may reverse cardiac damage

What the researchers found

Metabolic disorders amplify cardiomyopathy through energetic imbalance, inflammation, and fibrosis. SGLT2i and GLP-1 RA promote reverse remodeling by targeting these converging mechanisms with pleiotropic effects beyond neurohormonal blockade.

Why it matters

Cardiomyopathy patients often have unaddressed metabolic disorders. Treating the metabolic component with GLP-1/SGLT2 drugs could slow or reverse heart disease progression.

How the study worked

Review of metabolic-cardiomyopathy interactions, molecular pathways, and therapeutic innovations including SGLT2i, GLP-1 RA, and non-steroidal MRA.

What this study cannot tell us

Review. Limited clinical trial data for GLP-1/SGLT2 specifically in genetic cardiomyopathies. Optimal therapy combinations unknown.

How to read the evidence

Review integrating genetic, molecular, and clinical evidence. Emerging therapeutic area.

When this study was published

Published in 2025.

The bigger picture

Cardiomyopathies are no longer purely genetic diseases — metabolic factors determine disease severity, and metabolic drugs can modify outcomes.

Questions still open

Should all cardiomyopathy patients be screened for metabolic disorders?
Would GLP-1 drugs improve specific cardiomyopathy subtypes?
Can metabolic therapy prevent disease onset in mutation carriers?

Common questions

Can diabetes drugs help genetic heart conditions?

Emerging evidence suggests yes. GLP-1 and SGLT2 drugs target the metabolic pathways that worsen genetic cardiomyopathies, potentially slowing or even reversing heart disease progression.

Why does metabolism matter for genetic heart disease?

Metabolic disorders like obesity and diabetes amplify the effects of cardiomyopathy genes through inflammation, energy imbalance, and fibrosis — making genetic heart disease worse than it would be otherwise.

Read the original research

Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA.

Current cardiology reports, 28(1), 21

View on PubMed ↗Publisher’s paper ↗

Citation

Indennidate, Carla; Perencin, Brigitta; Di Maso, Vittorio; Buda, Iris; Candido, Riccardo; Sinagra, Gianfranco; Merlo, Marco. (2026). Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA.. Current cardiology reports, 28(1), 21. https://doi.org/10.1007/s11886-025-02340-6